Hybrid Seminar - Richard Pomeranz

Dr. Richard Pomerantz is pictured.
March 21, 2022 - 12:00pm
601 Fairchild or Join Over Zoom

Department of Biochemistry and Molecular Biology

Sidney Kimmel Cancer Center

Thomas Jefferson University

Host: Carol Prives

Title: Pol-theta: a cancer drug target with reverse transcriptase activity

Abstract: DNA polymerase theta (Polq) is a unique DNA repair protein with DNA helicase and DNA polymerase enzymatic activities. Polq promotes translesion DNA synthesis and the repair of DNA double-strand breaks via microhomology-mediated end-joining (MMEJ). Polq expression is essential for the proliferation of BRCA1/2 mutated cancer cells, but is dispensable for normal cells. Polq is therefore an ideal cancer drug target and the first Polq inhibitor is currently being tested in clinical trials to treat cancers harboring BRCA1/2 mutations. We made the unexpected discovery that Polq exhibits robust reverse transcriptase activity like HIV RT, and promotes RNA-templated DNA repair in mammalian cells. The structural and molecular basis of Polq RT activity will be presented as well as drug development research targeting this enzyme as a next generation precision medicine target.

Hybrid seminar. Limited in-person attendance in room 601 Fairchild. Others are encouraged to join over Zoom. Please email [email protected] for a Zoom link for this seminar.

Business Office

Department of Biological Sciences
500 Fairchild Center
Mail Code 2401
Columbia University
1212 Amsterdam Avenue
New York, NY 10027

Academic Office

Department of Biological Sciences
600 Fairchild Center
Mail Code 2402
Columbia University
1212 Amsterdam Avenue
New York, NY 10027
[email protected]
212 854-4581